CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway by Li, Y et al.
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Abstract (193 words) 
Fatty acid translocase CD36 (CD36) is a multifunctional membrane protein that facilitates the 
uptake of long-chain fatty acid (LCFA). Lipophagy is autophagic degradation of lipid droplets. 
Accumulating evidence suggests that CD36 is involved in the regulation of intracellular signal 
transduction that modulates fatty acid storage or usage. However, little is known about the 
relationship between CD36 and lipophagy. In this study, we found that increasedCD36 expression 
was coupled with decreased autophagy in the livers of mice treated with a high-fat diet. 
Overexpressing CD36 in HepG2 and Huh7 cells inhibited autophagy, while knocking down CD36 
expression induced autophagy due to the increased autophagosome formation in autophagic flux. 
Meanwhile, knockout of CD36 in mice increased autophagy while reconstruction of CD36 
expression in CD36-knockout mice reduced autophagy. CD36 knockdown in HepG2 cells 
increased lipophagy and β-oxidation, which contributed to improving lipid accumulation. In 
addition, CD36 expression regulated autophagy through the AMPK pathway with 
phosphorylation of ULK1/Beclin1 also involved in the process. These findings suggest that CD36 
is a negative regulator of autophagy and induction of lipophagy by ameliorating CD36 expression 
can be a potential therapeutic strategy for the treatment of fatty liver diseases through attenuating 
lipid over-accumulation. 





Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, 
with prevalence estimates ranging from 25% to 45%.(1) NAFLD is considered to be the liver 
manifestation of metabolic syndrome, which encompasses a wide spectrum beginning with 
steatosis.(2, 3) The cluster of differentiation 36 (CD36), belongs to the scavenger receptor family, 
also known as fatty acid translocase (FAT), facilitating the uptake of long chain fatty acid (LCFA) 
and is widely expressed on the surface of many cell types in vertebrates.(4, 5) CD36 recognizes 
different ligands and may promote different intracellular signalling pathways. This 
multifunctional membrane glycoprotein has been studied extensively in relation to its role in the 
uptake of LCFA, which is involved in the NAFLD. Hepatic CD36 expression is significantly 
elevated in animal models and patients with NAFLD, regarded as positively correlated with liver 
fat content and insulin resistance.(6) 
 
Accumulating evidence indicates that CD36 is not only a fatty acid transporter but is also 
emerging as an essential regulator of intracellular fatty acid homeostasis. Recent studies found 
that CD36 is involved in fatty acid oxidation by the activation of adenosine 
monophosphate-activated protein kinase (AMPK),(7) suggesting that it modulates fatty acid 
storage or usage. It has also been reported to function as a pattern recognition receptor (PRR) that 
conducts intracellular signals and activates inflammatory pathways such as Toll-like receptor 
(TLR), nuclear factor-кB (NF-кB), and c-Jun N-terminal kinase (JNK) signals to control the 
chronic metabolic inflammatory response,(8-11) confirming its significance in the pathogenesis 
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of non-alcoholic steatohepatitis (NASH).  
 
Cell autophagy maintains organelle quality control by engulfing and degrading damaged 
intracellular components and cytoplasmic contents such as proteins,(12) glycogen,(13) and lipid 
droplets.(14, 15) Impaired autophagy has been linked to the initial development of hepatic 
steatosis and the progression of steatosis to liver injury.(14, 16, 17) Inhibition of autophagy by 
genetic knockdown of the autophagy geneAtg5,or pharmacological inhibition with an autophagy 
inhibitor, significantly increased cellular triglyceride content,(14, 17) thus, autophagy is identified 
to play a central rolein the breakdown of hepatic lipid droplet-stored triglyceride and cholesterol 
by lipophagy.(17) This is an alternative pathway of lipid metabolism acting via the lysosomal 
degradative pathway of autophagy, degrading lipid droplet triglyceride and cholesterol by 
lysosomal acidic hydrolases. The free fatty acid generated by lipophagy from the breakdown of 
triglycerides then fuel cellular rates of mitochondrial β-oxidation. Decreased liver lipophagy 
aggravates hepatic lipid over-accumulation and an increased incidence of NAFLD.(14) Although 
CD36 has been confirmed to contribute to the CD5L-mediated macrophage autophagy 
significantly,(18) the relationship between CD36 and autophagy/lipophagy is largely unknown. 
The potential role of CD36 in regulating lipophagy has never been addressed in NAFLD.  
 
AMPK, a serine–threonine kinase, functions as an energy and metabolic sensor in maintaining 
metabolic homeostasis.(19) Activation of AMPK occurs primarily through phosphorylation of its 
catalytic α subunit at the Thr172 residueby liver kinase B1 (LKB1) or by 
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Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ).(20, 21) In addition to the role of 
AMPK as a regulator of energy homeostasis, growing evidence has implicated AMPK in the 
regulation of various physiologic and pathologic pathways such as lipid metabolism, 
mitochondrial biogenesis, gene expression, and protein synthesis.(22, 23) In the autophagy 
process, AMPK directly phosphorylates unc-51 like autophagy activating kinase 1 (ULK1) at 
sitesSer317, Ser555, andSer777, and phosphorylates Beclin1 at site S91/S94 to activate the 
pro-autophagy Vps34 complex, which is critical for its function in autophagy.(19, 24-26) 
Moreover, AMPK indirectly activates autophagy by suppressing the activity ofthe mammalian 
target of rapamycin complex 1 (mTORC1), whose high activity prevents the activation of ULK1 
by phosphorylating ULK1 at Ser 757 and disrupts the interaction between ULK1 and AMPK.(25) 
Interestingly, the role of CD36 in enhancing fatty acid oxidation appears linked to CD36 AMPK 
inter-regulation.(27) CD36 was shown to be important for coordinating the dynamic protein 
interactions within a molecular complex consisting of the CD36 partner tyrosine kinase Fyn, the 
AMPK kinase LKB1 and AMPK. CD36 expression maintains AMPK quiescence by allowing Fyn 
to access and phosphorylate LKB1, promoting its nuclear sequestration away from AMPK. LCFA 
binding to CD36 activates AMPK within minutes via its ability to dissociate Fyn from the 
complex as CD36 is internalized into LKB1-rich vesicles. An earlier work from our group found 
that CD36 translocation to the plasma membrane of hepatocytesis associated with a low AMPK 
activity, accompanying a low hepatic fatty acid oxidation, which may also result from the 
increased LKB1 phosphorylation.(11) These studies lead to the reasonable speculation that CD36 




In this study, we aimed to investigate the regulatory action of CD36 in autophagy/lipophagy and 
its underlying molecular mechanism invitro and in vivo. Our results demonstrate that hepatocyte 
CD36 has a negative role in the regulation of lipophagy through an AMPK-dependent pathway. 
This suggests that correction of the autophagy deficiency by ameliorating CD36 expression in 




Materials and Methods 
Chemicals and reagents 
Palmitic acid (PA) (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in10% bovine serum 
albumin (BSA) with a stock concentration of 5 mM, aliquoted and stored at - 20°C. Chloroquine 
(CQ) (Sigma-Aldrich) inhibits lysosomal acidification and therefore prevents autophagy by 
blocking autophagosome fusion and degradation, which was dissolved in ddH2O with a stock 
concentration of 50 mM and stored at 4°C. Wortmannin (Sigma-Aldrich), a PI3K inhibitor, was 
dissolved in DMSO with a stock concentration of 400 µM at - 80°C. Compound C (Selleck 
Chemicals, Texas, America) was dissolved in DMSO and stored at - 80°C. Bodipy 492/502 
(Invitrogen, Carlsbad, America) was dissolved in DMSO and stored at - 20°C. LysoTracker was 
purchased from Life Technology (Grand Island, NY, USA). 
Cell culture 
Hepatocytes (HepG2 and Huh7 cells) were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (HyClone, Logan, Utah, America) supplemented with 10% foetal bovine serum (FBS) 
(Natocor, Corcovado, Argentina). Cells were cultured at 37°C in a humidified atmosphere with 5% 
v/v CO2. Stable cell lines (HepG2 and Huh7 stable cell lines) were constructed with the lentivirus 
constructs including GV341 empty vector and GV341 vector containing CD36, respectively. 
Stable cell lines were also cultured according to the above methods. Western blotting, qPCR, 
immunofluorescence, lipid droplets staining and autophagic flux analysis in cells were performed 




CD36-/- mice created on a C57BL/6J background were kindly provided by Dr Maria Febbraio 
(Lerner Research Institute, U.S.). Eight-week-old male C57BL/6J or CD36-/- mice were fed with 
NCD (n=6) or HFD (n=6) for 14 weeks (research diets D12450B, 12492). In the experiment of 
reconstructing CD36 expression in CD36-/- mice, the 8-week-old male CD36-/- mice were 
injected with lentivirus empty vector (n=6) or lentivirus vector containing CD36 (n=6) in the tail 
vein and kept on HFD for 8 weeks. All mice were housed in a temperature-controlled 
environment and 12 h: 12 h light: dark cycle with free access to diet and water. Before sacrifice, 
mice with free access to water were deprived of food overnight. Animal treatment conformed to 
the guidelines of the Institutional Animal Care and Use Committee of Chongqing Medical 
University. All animals received care according to the criteria for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23). 
Gene silencing 
Knockdown of CD36 in HepG2 cells was achieved by using a reverse siRNA transfection 
procedure performed in six-well plates. Therefore, for each well to be transfected, 5μl 
Lipofectamine RNAiMAX (Life Technologies, Thermo Fisher Scientific, Eugene, Oregon, USA) 
were mixed with 500μl Opti-MEM (Gibco, Thermo Fisher Scientific, Eugene, Oregon, USA) and 
combined with 25 pmol siRNA (Genepharma, Shanghai, China). The transfection mixture was 
incubated at room temperature for 20min. HepG2 cells were harvested in complete growth 
medium without antibiotics and diluted so that 2ml contained the appropriate number of cells to 
give 30-50% confluence 24 hours after plating. Cell suspension were mixed with the transfection 
mixture and incubated. CD36-knockdown Huh7 cells were achieved by using a forward 
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transfection procedure according to the product specification. 
Western blot analysis 
Lysis of cells and mouse liver tissue were achieved with RIPA lysis buffer. Whole cell extracts 
containing 30 μg protein per lane were dissolved on an 8% or 12% acrylamide gel and blotted 
wetly onto a polyvinyl difluoride (PVDF) membrane (Immobilon-P, 0.2 μm or 0.45 μm, Merck 
Millipore, Darmstadt, Germany). Membranes were blocked with 3% BSA for 1h at room 
temperature and probed with specific antibodies overnight at 4°C (anti-LC3B: 1:2000, #L7543, 
Sigma; anti-p62: 1:5000, #ab109012, Abcam; anti-CD36: 1:2000, #NB600-1423, Novus 
Biologicals; anti-CPT1a: 1:1000, #15184-1-AP, Proteintech; anti-AMPK: 1:1000, #5832, CST; 
anti-Phospho-AMPKα (Thr172): 1:1000, #2535, CST; anti-LKB1: 1:3000, #ab199970, Abcam; 
anti-mTOR: 1:1000, #2983, CST; anti-Phospho-mTOR (Ser2448): 1:1000, #5536, CST; 
anti-FOXO1: 1:500, #05-107, Millipore; anti-Phospho-FOXO1(S256): 1:1000, #9461, CST; 
anti-ATG7: 1:1000, #8558, CST; anti-ULK1: 1:1000, #8054, CST; anti-Phospho-ULK1(Ser555): 
1:1000, #5869, CST; anti-Beclin1: 1:1000, #3495, CST; anti-Phospho-Beclin1(Ser93): 1:1000, 
#14717, CST; anti-β actin: 1:3000, # 20536-1-AP, Proteintech). Detection was achieved by using 
appropriate HRP-conjugated secondary antibodies (1:8000, Proteintech) in conjunction with the 
ECL reagent (Clarity Western ECL, Bio-Rad Laboratories). Afterwards, membranes were 
exposed and quantification of signals was performed using an Image Analyzer. 
Immunofluorescence assay 
Prior to treatment, cells were seeded on glass coverslips. Following treatment, cells were washed 
in PBS, fixed for 25 minutes in 4% formaldehyde, and washed thrice. Cells were then 
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permeabilized in 100% methanol at -20°C for 10 minutes, washed, and blocked in normal goat 
serum for 1 hour. Cells were then incubated with primary antibody overnight at 4°C, washed with 
PBS, and then incubated for 2 hours at room temperature with fluorescence-conjugated secondary 
antibodies. Cells were washed thrice and then treated with DAPI for five minutes, followed by 
three washes with PBS. For experiments involving lipid droplet staining, cells were stained with 
fluorescent lipid dye, Bodipy 492/502 at a 1:1000 dilution for 30 minutes at room temperature 
before DAPI staining. Coverslips were visualized using a Leica confocal microscope. 
Autophagic Flux Analysis 
HepG2 or Huh7 cells were treated with siCD36 or siNeg and grown for 72 hours. During the last 
24h of incubation prior to the experiment, the cells were either untreated or treated with 10 µM 
CQ. Autophagy was assessed by combinatory detection of the autophagosome formation marker 
LC3II, along with p62. In another experiment to detect autophagic flux, HepG2 cells were first 
transduced with siCD36 or siNeg in a confocal dish. Twenty-four hours after the 1st transduction, 
the cells were then transduced with mRFP-GFP-LC3 adenoviral vectors, which were purchased 
from HanBio Technology (Shanghai, China) according to the manufacturer’s instructions. The 
principle of the assay is based on different pH stability of red and green fluorescent proteins. The 
EGFP fluorescent signal could be quenched under the acidic condition (pH below 5) inside the 
lysosome, whereas the mRFP fluorescent signal did not change significantly in acidic conditions. 
In red and green -merged images, autophagosomes are shown as yellow puncta, while 
autolysosomes are shown as red puncta. An enhancement of both yellow and red puncta in cells 
indicate that autophagic flux is increased, while autophagic flux is blocked when only yellow 
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puncta are increased without alteration of red puncta, or when both yellow and red puncta are 
decreased in cells.(28, 29) HepG2 cells were incubated in 1ml growth medium with the 
adenoviruses for 2 hr at 37°C, and the growth medium was replaced with fresh medium. 
Experiments were performed 48 hours after the 2nd transduction. LC3 puncta were examined 
with a Leica confocal microscope. 
Electron Microscopy 
Fresh tissue was placed in 4% glutaraldehyde overnight at 4°C. Ultra-thin sections were cut and 
then stained. Images were acquired on a transmission electron microscope. For quantification of 
autophagy, autophagic vacuoles (defined as autophagosomes, double-membraned structures 
surrounding cytoplasmic material, and autolysosomes, lysosomes containing cytoplasmic material) 
were counted. 
Measurements of oxygen consumption rate 
Oxygen consumption was measured on a Seahorse XF24 analyser at 37°C. XF Seahorse XF Cell 
Mito Stress Test Kit (103015-100), Seahorse XFe24 FluxPak mini (102342-100), Seahorse XF 
Base Medium (102353-100) was purchased from Agilent (California, USA). Forty-eight hours 
before assays, 40,000 cells of siCD36 or siNeg treated HepG2 cells were seeded in a Seahorse 
XF24 analyser plate. To study the effects of fat treatment on cells, media was replaced with media 
containing 0.2% BSA and 0.5 mM palmitic acid 24 h before analysis. On the day of the assay, 
media was replaced with Seahorse assay media. Oxygen consumption rate(OCR) was measured 
in the basal state and following oligomycin treatment, FCCP treatment and 
Rotenone/Antimycin-A treatment. Basal respiration and maximal respiration were calculated 
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respectively. ATP production was calculated by subtracting minimum rate measurement after 
oligomycin injection from the last rate measurement in the basal state. Following the assay, cells 
were lysed, and protein content was taken for normalization. 
TG contentassays 
The assay was performed with a TG Assay kit according to the manufacturer’s instructions 
(Nanjing Jiancheng Bioengineering Institute, Nanjing, China). 
Immunocytochemistry 
Prior to treatment, cells were seeded on glass coverslips. Following treatment, cells were washed 
in PBS, fixed for 15 minutes in precooled acetone, and washed thrice. Cells were then 
permeabilized in 0.5% Triton X-100for 10 minutes and washed. Endogenous peroxidases were 
inactivated using 3% H2O2, followed by blocking with goat serum. Cells were incubated 
overnight at 4°Cwith TFEB antibody (1: 100, Proteintech, Wuhan, China). Then, cells were 
washed and incubated for 45 min with secondary antibody. Cytochemical reactions were 
performed using a diaminobenzidine kit and cells were counterstained with hematoxylin. Images 
were captured using a Zeissmicroscope (Zeiss, Jena, Germany). 
Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s 
instructions. Then, 1 μg total RNA was reverse-transcribed to obtain cDNA using PrimeScript® 
RT reagent Kit (TaKaRa) according to the manufacturer’s protocol. Quantitative real-time PCR 
was performed using SYBR Green PCR Mix kit (TaKaRa). Specific primer sequences used for 
real-time PCR were listed in Table 1. The housekeeping gene of β-actin was used for 
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normalization in cultured cells, whereas 18sRNA expression was used for normalization in mouse 




All cell culture experiment data represent at least three independent experiments and were 
expressed as the means ± SD. The difference between two groups was statistically analysed using 
Student’s t-test in GraphPad Prism 5. Statistical tests of significance were given in the legends of 




1. The CD36 expression in the liver of mice treated with high-fat diet (HFD) was increased 
and LC3II, an autophagosome marker, was decreased. 
Eight-week-old C57BL/6 mice were fed with HFD for 14 weeks to induce the NAFLD model. 
Liver section data showed evident steatosis in the livers of HFD-treated mice compared with the 
normal chow diet (NCD)-treated mice by haematoxylin & eosin staining (HE) and Oil Red O 
staining (ORO) (Fig. 1A). Triglyceride (TG) and free fatty acid (FFA) contents were significantly 
higher in HFD-treated mouse livers than in NCD-treated mouse livers (Fig. 1B). To determine 
CD36 expression and the status of autophagy in NAFLD, we performed Western blotting to 
detect CD36 and LC3II in mice with liver steatosis and corresponding controls and found that the 
expression of CD36 was increased and LC3II level was significantly reduced in liver steatosis 
mice. Furthermore, we observed an increase in the protein levels of SQSTM1/p62, one of the 
selective substrates of autophagy, which was commonly used as a marker of autophagic flux (Fig. 
1C). These data suggested that there may be a negative correlation between the expression of 
CD36 and autophagy in vivo.  
2. Down-regulation of CD36 increased autophagy and up-regulation of CD36 inhibited 
autophagy in HepG2 and Huh7 cells. 
Next, we transfected HepG2 and Huh7 cells with siRNAs targeting CD36 (siCD36) to 
knockdown CD36 expression and observed an increase in LC3II protein and a decrease in p62 
level under the PA treatment conditions (Fig. 2A, B). We also observed an increase in LC3II 
protein and a decrease in p62 level after down-regulating the CD36 expression in the HepG2 cells 
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without PA treatment (Supplemental Figure S1A). Meanwhile, we constructed CD36 
overexpressing (CD36 OE) stable cell lines both in both HepG2 and Huh7 cells, finding that 
CD36 OE in both cells with PA treatment reduced LC3II expression and increased p62 
accumulation (Fig. 2C, D). To further confirm autophagy changes, we detected the LC3 puncta 
following immunofluorescence staining. An increase in LC3 puncta was observed in siCD36 
HepG2 and Huh7 cells with PA treatment (Fig. 2E). Since the increase in LC3II levels by 
immunoblot analysis could be due to either the induced formation or the decreased clearance of 
autophagosomes, we treated siCD36 and negative control (siNeg) HepG2 and Huh7 cells with the 
lysosomal inhibitor chloroquine (CQ) in the presence of PA. We observed increased LC3II and 
decreased the accumulation of p62 in both CD36 knockdown cells, and we observeda relative 
increase in LC3II level and decreased p62 after using CQ when these same cells were compared 
to siNeg cells (Fig. 2F). These data suggested that an increase in autophagosome formation had 
occurred in CD36 knockdown cells, thereby inducing autophagic flux. To further support this 
finding, we transfected siCD36 and siNeg HepG2 cells with mRFP-GFP-LC3 adenoviral vectors 
that fluoresce both red and green (yellow) in autophagosomes and only red in autolysosomes and 
then treated them with 0.5 mM PA for 24h. We observed an increase in the numbers of both 
yellow and red puncta in siCD36 HepG2 cells compared to control cells, suggesting an increase 
in autophagosome formation (Fig. 2G). Taken together, these data supported the notion that 
autophagosome induction was due to increased formation rather than decreased clearance in the 
CD36 knockdown cells. 
3. The CD36 knockout in mice increased liver autophagy, and its reconstruction in CD36 
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knockout mice reduced autophagy. 
To further confirm the relationship between CD36 and autophagy in vivo, we detected CD36, 
LC3II and p62 protein levels in the livers of CD36 knockout mice (CD36-/- mice) and wild-type 
mice (WT mice). In both the NCD and HFD conditions, we observed a very significant increase 
in LC3II expression and a pronounced reduction in p62 protein level in the livers ofCD36-/- mice 
compared to WT mice (Fig. 3A, B). This suggested that deficiency of CD36 vigorously promoted 
autophagy. After reconstruction of CD36 expression with lentivirus vectors (CD36OE) in 
CD36-/- mice, ultrastructural analysis by electron microscopy showed a decrease in numbers in 
autophagic vacuoles (defined to include autophagosomes and autolysosomes) in the livers, and 
there were more autophagosomes and autolysosomes in the livers of CD36-/- mice injected with 
lentivirus empty vector (Vector) (Fig. 3C). Interestingly, in the livers of CD36-/- mice injected 
with lentivirus empty vector, we found that autolysosomes engulfed lipid droplets. Thus, we 
determined that lipophagy occurred in CD36-/- mouse livers. 
4. Lipophagy was induced by the CD36 knockdown in HepG2 cells, followed by enhanced 
β-oxidation, while inhibition of autophagy with wortmannin (WM) reduced lipophagy and 
β-oxidation. 
CD36 knockdown in HepG2 cells exhibited a significant increase in autophagy coupled with a 
decrease in PA treated lipid droplets. Although the reduction of intracellular lipid content may be 
partially due to decreased fatty acid uptake, increased β-oxidation of fatty acid is also important 
for reduction of abnormal lipid accumulation. Lipophagy engulfing lipid droplets has been linked 
to reduced lipid content and increased β-oxidation. In this connection, we noted an increase in 
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autophagosomal (LC3/Bodipy) and lysosomal (Lysotracker/Bodipy) lipid in siCD36 HepG2 cells 
after loading 0.5mM PA for 24 hours, but disappearance in siCD36 HepG2 cells treated with 
wortmannin (Fig. 4A, B, C). Furthermore, we measured the oxygen consumption rate and found 
that CD36 knockdown in HepG2 cells also increased basal respiration, maximal respiration and 
ATP production compared with control HepG2 cells when pre-treated with lipids, and inhibition 
of autophagy reversed the situation (Fig. 4D,E). These data suggested that CD36 knockdown 
increased lipophagy and β-oxidation, subsequently contributing to reducing lipid accumulation, 
and inhibition of autophagy decreased lipophagy and β-oxidation, thereby aggravating lipid 
accumulation. To further confirm the effect of CD36-mediated lipophagy on lipid content, we 
detected the intracellular TG level in HepG2 cells of the three groups after PA treatment, the 
results showed that CD36 knockdown decreased TG content and inhibition of autophagy in 
siCD36 HepG2 cells increased TG content (Fig. 4F). Moreover, the protein level of CPT1a, a 
rate-limiting enzyme for fatty acid oxidation, was increased in both the HFD and NCD fed CD36 
-/- mice (Fig. 4G, Supplemental Figure S1B).With or without PA treatment, CD36 knockdown 
increased the CPT1a protein expression (Fig. 4H, Supplemental Figure S1C). The mRNA level 
of CPT1a was increased in the livers of CD36-/- mice fed with HFD compared to WT mice (Fig. 
4I). These data suggested that the deletion of CD36 increased fatty acid oxidation. 
5.The AMPK pathway was activated in CD36 knockdown hepatocytes and CD36 knockout 
mouse livers. 
We next investigated classical signaling pathways known to regulate autophagy. Phosphorylation 
of AMPK at site Thr172in livers of mice fed with HFD was lower than that of mice fed with NCD 
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(Fig. 5A). CD36-/-mouse livers under HFD showed a significant increase in phosphorylation of 
AMPK, suggesting that knockout of CD36 activated the AMPK pathway (Fig. 5B). To further 
confirm the AMPK pathway, we detected p-AMPK (Thr172) and total AMPK protein levels in 
siCD36 HepG2 and control cells. Compared with the control group, there was a significant 
increase of p-AMPK (Thr172) level in siCD36 HepG2 cells whether in the presence of PA or in 
the absence of PA (Fig. 5C, Supplemental Figure S1D), confirming that the AMPK pathway was 
activatedin vitro. The serine/threonine kinase LKB1 is one of the major upstream kinases that 
activate AMPK by phosphorylating the Thr172 residue in AMPKα. We found that CD36 
knockdown cells showed a higher LKB1 protein level, which was consistent with AMPK activity 
(Fig. 5C). The autophagy markers, LC3II and p62, were reversed when AMPK was inhibited by 
the AMPK inhibitor Compound C (CC) in siCD36 HepG2 cells under the condition of PA 
treatment (Fig. 5D), which was accompanied by a rebound of lipid accumulation (Fig. 5E). 
6. Reducing CD36 expression increased autophagy through the phosphorylation of 
ULK1/Beclin1 in vitro. 
AMPK promotes autophagy partly by suppressing mTOR or increasing the transcriptional activity 
of FOXO1. However, we found that siCD36 HepG2 cells showed no noticeable difference in 
p-mTOR and mTOR levels compared with siNeg cells (Fig. 6A). Simultaneously, the protein and 
mRNA expressions of the transcription factor FOXO1were not increased in siCD36 HepG2 cells, 
and the phosphorylation of FOXO1 was increased in siCD36 HepG2 cells, but the interacting 
protein ATG7 was not increased (Fig. 6A, B). In addition, the mRNA screening results of several 
autophagy-related genes (ATGs) showed that ULK1 and Beclin1 were induced in siCD36 HepG2 
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and Huh7 cells (Fig. 6C, D). The results from CD36-/- mouse liver tissue also confirmed this 
finding (Fig. 6E). We tested the protein expression and phosphorylation level of ULK1 and 
Beclin1 in siCD36 HepG2 and Huh7 cells. CD36 knockdown in HepG2 cells significantly 
increased ULK1 expression and phosphorylation (Ser555) (Fig. 6F), and inhibition of AMPK 
with CC reversed the expression and phosphorylation level of ULK1 (Fig. 6G). Meanwhile, 
knockdown of CD36 in Huh7 cells induced Beclin1 expression and phosphorylation (Ser93) (Fig. 
6H), suggesting that CD36 knockdown induced autophagy through the AMPK-ULK1/ Beclin1 
pathway. Furthermore, we also observed an induced nuclear TFEB after down-regulating CD36 
expression, suggesting that an induction in nuclear TFEB may be also contributing to the 





Lipid over-accumulation is the hallmark of NAFLD. CD36 is an important membrane 
glycoprotein facilitating fatty acid uptake.(4, 30) In addition to the function of fatty acid 
translocase, CD36 plays an important role in mediating signal transduction, acting as a regulator 
of the inflammatory response and modulating fatty acid β-oxidation, which contributes to the 
maintenance of cellular fatty acid homeostasis.(7) Impaired autophagy in the liver has been 
connected with disorders of lipid over-accumulation.(14) In fatty livers, a variety of factors can 
regulate autophagy, such as insulin resistance, oxidative stress, excess triglycerides and free fatty 
acids.(16, 31, 32) However, the relationship between CD36 and liver autophagy is still unknown. 
Our study is the first to demonstrate that CD36 negatively regulates autophagy in mouse livers 
and hepatocytes. 
 
Autophagy is characterized as a selective, bulk degradative system engulfing cytosolic materials, 
and selective autophagy regulates hepatic metabolic pathways.(33) Lipophagy is a form of 
selective autophagy that pinches off part of a lipid droplet and fuses it with a lysosome.(14) 
Lipophagy promotes lipolysis, which is subsequently catabolised by β-oxidation to produce 
energy and ketone bodies so could function as a hepatocyte defence mechanism against NAFLD. 
Enhancement of autophagy using rapamycin, carbamazepine and other pharmaceutical agents 
alleviates liver steatosis.(31, 34-36) Our study now demonstrates that CD36 knockdown in 
hepatocytes upregulates autophagy, which reduces lipid accumulation by facilitating β-oxidation 
of fatty acid. We have provided evidence for a novel autophagy-dependent mechanism of CD36 
22 
 
knockdown that attenuates PA-induced lipid accumulation. Moreover, we have shown that 
inhibition of autophagy in hepatocytes is involved in lipid accumulation by perturbing 
β-oxidation of fatty acid. 
 
The mechanism of increased autophagy in CD36 knockdown hepatocytes and CD36 knockout 
mice is probably multifactorial. Our results reveal that CD36 knockdown/knockout is associated 
with AMPK activation in hepatocytes and mouse livers. These observations is consistent with the 
report that reduction of CD36 expression induces AMPK activation.(7) Stimulation of AMPK 
pathways is a pro-autophagic classical mechanism that occurred both in vitro and in vivo. Our 
data reveal that AMPK activation plays a significant role in CD36 knockdown-induced autophagy 
and subsequent attenuated lipid accumulation. 
 
Activation of AMPK is one of the major mechanisms accounting for autophagy induction. AMPK 
promotes autophagy partly by suppressing the mTOR pathway, negative regulator of autophagy 
that phosphorylates ULK1 at Ser 757. Our data show no obvious change of p-mTOR and mTOR 
protein levels, indicating that the mTOR pathway may not be involved in CD36 
knockdown-induced autophagy. Mammalian FOXO transcription factors, including FOXO1, 
FOXO3a, FOXO4 and FOXO6, function critically in the regulation of metabolism, cell cycle 
arrest and oxidative stress resistance.(37) FOXO1 is also largely known as an important 
transcription factor to induce autophagy.(38) The activation of AMPK can regulate the activation 
of FOXO1.(39, 40) However, our results reveal that CD36 knockdown in HepG2 cells reduces 
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the mRNA and protein expression of FOXO1 but increases the level of p-FOXO1. A large number 
of studies have reported that cytoplasmic p-FOXO1 is inactivated. However, Wang noted that 
p-FOXO1 is located in the cytoplasm of iNKs and interacts with ATG7, leading to the induction 
of autophagy, which was independent of the transcriptional activity of FOXO1.(41) ATG7 is an 
E1-like enzyme activating the ubiquitin-like molecule ATG12 and driving the conjugation of 
ubiquitin-like molecule LC3 to the lipid phosphatidylethanolamine.(42) Therefore, we detected 
ATG7 expression. However, our data show no obvious ATG7 change, suggesting that FOXO1 
transcriptional function and the interaction between p-FOXO1 and ATG7 may not be involved in 
CD36 knockdown-induced autophagy. We detected several important autophagy-related genes in 
HepG2 and Huh7 cells and mouse livers. The results showed that ULK1 and Beclin1 mRNA 
expressions were increased, implying that a transcriptional mechanism may be involved in the 
upregulation of autophagy. The ATG1/ULK1 complex plays a crucial role in autophagy induction, 
integrating signals from upstream sensors such as AMPK and transducing them to the 
downstream autophagy pathway. The protein kinase activity of ULK1 is required for its 
autophagic function.(43) Research shows that in most cases, AMPK activation promotes 
autophagy by directly binding to and phosphorylating ULK1 at multiple residues such as Ser317, 
Ser555, and Ser777, and AMPK can also indirectly promote autophagy by reducing the inhibition 
of mTOR on ULK1 activity through phosphorylating ULK1 at Ser757.(24, 25, 44) Our data 
showed that phosphorylation of ULK1 at Ser555 and the protein expression of ULK1 in HepG2 
were significantly increased after CD36 knockdown. Administration of Compound C attenuated 
CD36 knockdown-induced increase in ULK1 expression and phosphorylation. In Huh7 cells, 
24 
 
protein level and phosphorylation of Beclin1 were increased, which is critical for Vps34 complex 
formation to induce autophagy. These results suggest that CD36 knockdown activates autophagy 
through the AMPK–ULK1/ Beclin1 signalling pathway in hepatocytes. TFEB is a key positive 
regulator of autophagy and lysosome biogenesis, and nuclear TFEB induction may be contributed 
to the increased autophagy. Some reports suggest that the nuclear localization of TFEB is directly 
regulated by mTOR to activate autophagic gene expression.(45) Another study reported that 
ezetimibe induced nuclear TFEB translocation in tsc2-/- MEFs and ezetimibe could still induce 
autophagy through AMPK activation and TFEB nuclear translocation, related to an independent 
mTOR ameliorative effect and the MAPK/ERK pathway.(46) In this study, nuclear TFEB was 
induced after down-regulating CD36 expression. However, the change of mTOR was not 
observed. Whether the induced nuclear TFEB is involved in the increased autophagy and more 
details about the pathways of TFEB participating in or AMPK-TFEB axis in CD36-mediated 
autophagy need further study in our future research. 
 
Given that CD36 plays an important role in modulating fatty acid β-oxidation, which acts as a 
contributor to maintain cellular fatty acid homeostasis, our results provide evidence for a novel 
lipophagy-dependent mechanism by which down-regulation of CD36 attenuates cellular lipid 
over-accumulation by promoting β-oxidation of fatty acid. CD36 is a fatty acid translocase, which 
facilitates the uptake of LCFA. The cell uptake of saturated fatty acid and unsaturated fatty acid 
also affects autophagy.(47) Exposing cells to saturated fatty acid induced the canonical, 
BECN1/PI3K dependent autophagy pathway, and the unsaturated fatty acid oleate triggered 
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autophagic responses that were independent of the BECN1/PI3K complex. Accordingly, we 
speculated that the uptake of fatty acid in siCD36 cells and CD36-\- mice might also be involved 
in autophagy. We have also performed experiments to detect autophagy after down-regulating 
CD36 expression in hepatocytes without PA treatment and in CD36-/- mice fed with NCD, and 
the similar results were obtained compared with that in the condition of PA treatment and in 
CD36-/- mice fed with HFD. Our main aim was to investigate the regulatory action of CD36 on 
autophagy/lipophagy in cell and mouse models of NAFLD. We observed that lipophagy occurred 
in the CD36 knockdown cells with PA treatment and in the livers of HFD fed CD36-/- mice. The 
putative effects of blocking lipid uptake on autophagy in siCD36 cells and CD36-\- mice need 
further experimental exploration. 
 
In conclusion, we have demonstrated that knockdown of CD36 in hepatocytes induces 
autophagydue to the increased autophagosome formation in autophagic flux, while 
CD36 overexpression inhibits autophagy. Lipophagy is increased through an AMPK-ULK1/ 
Beclin1 pathway in CD36 knockdown hepatocytes, which contributes to the increased 
β-oxidation and steatosis alleviation (Fig. 6I). In addition to the fatty acid uptake function of 
CD36, CD36 is a novel negative regulator of autophagy, and the reduced autophagy is a new 
mechanism for lipid accumulation in hepatocytes and livers of mice. These findings suggest that 
attenuating CD36 expression, which enhances clearance of fatty acid by induction of lipophagy in 
addition to the reduction of fatty acid uptake could be a potential therapeutic strategy for fatty 
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Table 1 qPCR Primer Sequences 
Genes Sequences 
human CD36 Forward: 5′- CTTTGGCTTAATGAGACTGGGAC -3′ 
Reverse: 5′- GCAACAAACATCACCACACCA -3′ 
human ULK1 Forward: 5′- AGCACGATTTGGAGGTCGC-3′ 
Reverse: 5′- GCCACGATGTTTTCATGTTTCA-3′ 
human Beclin1 Forward: 5′- CTCCTGGGTCTCTCCTGGTT-3′ 
Reverse: 5′- TGGACACGAGTTTCAAGATCC-3′ 
human ATG5 Forward: 5′- ACTGTCCATCTGCAGCCAC -3′ 
Reverse: 5′- TGCAGAAGAAAATGGATTTCG -3′ 
human ATG7 Forward: 5′- ATTGCTGCATCAAGAAACCC -3′ 
Reverse: 5′- GAGAAGTCAGCCCCACAGC -3′ 
human ATG12  Forward: 5′- CCATCACTGCCAAAACACTC -3′ 
Reverse: 5′- TTGTGGCCTCAGAACAGTTG -3′ 
human ATG16L1 Forward: 5′- AACGCTGTGCAGTTCAGTCC -3′ 
Reverse: 5′- AGCTGCTAAGAGGTAAGATCCA -3′ 
human ATG16L2 Forward: 5′- TGGACAAGTTCTCAAAGAAGCTG -3′ 
Reverse: 5′- CCTCAGTGCGACCAGTGAT -3′ 
human FOXO1 Forward: 5′-TCGTCATAATCTGTCCCTACACA -3′ 
Reverse: 5′-CGGCTTCGGCTCTTAGCAAA -3′ 
human β-actin Forward: 5′-GTTGTCGACGACGAGCG -3′ 
Reverse: 5′-GCACAGAGCCTCGCCTT -3′ 
mouse ULK1 Forward: 5′- AAGTTCGAGTTCTCTCGCAAG-3′ 
Reverse: 5′- ACCTCCAGGTCGTGCTTCT-3′ 
mouse Beclin1 Forward: 5′-GGCGAGTTTCAATAAATGGC-3′ 
Reverse: 5′-CCAGGAACTCACAGCTCCAT-3′ 
mouse CPT1a Forward: 5′-TGGCATCATCACTGGTGTGTT-3′ 
Reverse: 5′-GTCTAGGGTCCGATTGATCTTTG-3′ 
mouse 18sRNA Forward: 5′- TCGAGGCCCTGTAATTGGAA-3′ 





Figure 1. Hepatic CD36 expression is increased and autophagy is decreased in response to 
HFD treatment in mice. (A) HE staining (upper panel, original magnification, ×400) and Oil 
Red O staining (lower panel, original magnification, ×400). (B) Triglyceride (upper panel) and 
free fatty acid levels (lower panel) in mouse liver tissues. (C) Representative western blotting 
analysis of CD36, LC3II and p62 expression in mouse livers. n=6, data are presented as the 




Figure 2. Down-regulation of CD36 increases autophagy and up-regulation of CD36 inhibits 
autophagy in HepG2 and Huh7 cells with PA treatment. (A-B) LC3II and p62 protein levels 
after CD36 knockdown. (C-D) LC3II and p62 levels after CD36 overexpression. (E) 
Immunofluorescence staining with LC3 antibody. Fifty cells were used for statistical analysis of 
the number of LC3 positive puncta per cell. (F) LC3II and p62 protein levels after treatment with 
CQ in siNeg and siCD36 HepG2 or Huh7 cells. (G) Analysis of double fluorescent 
mRFP-EGFP-LC3 fusion protein expression to detect autophagic flux (yellow puncta represent 
autophagosomes and red puncta represent autolysosomes) in siNeg and siCD36 HepG2 cells. 
Fifty cells were used for statistical analysis of the number of autophagosome and autolysosome 
per transfected cell. Data were presented as the means ± SD, n=3, for (A, B, E, G), * represents p 
< 0.05 vs. siNeg groups; for (C, D), * represents p < 0.05 vs. NC groups; for (F), *represents 




Figure 3. CD36 knockout in vivo increases autophagy of mouse livers and its reconstruction 
in CD36 knockout mice decreases autophagy. (A) Western blotting analysis of LC3II and p62 
levels in CD36-/- and WT mice under NCD. (B) Western blotting analysis of LC3II and p62 
levels in CD36-/- and WT mice under HFD. (C) Ultrastructural analysis of the livers of the 
CD36-/- mice treated with lentivirus empty vector or lentivirus vector containing CD36. White 
arrowhead represents autophagic vacuoles (defined to include autophagosomes and 
autolysosomes) and red arrowhead represents intralysosomal lipid. Twenty fields were used for 
statistical analysis of the number of autophagic vacuoles per field. n=6, data were presented as the 





Figure 4. Knockdown of CD36 increases lipophagy and β-oxidation, inhibition of autophagy 
reduces lipophagy and β-oxidation. (A-C) Autophagosomal (LC3/Bodipy) and lysosomal 
(Lysotracker/Bodipy) co-localization with lipid under the condition of PA treatment. Thirty cells 
were used for statistical analysis of the number of confocal puncta per cell. (D-E) Oxygen 
consumption rate in HepG2 cells. (F) Intracellular TG content in HepG2 cells with PA treatment. 
(G) Western blotting analysis of CPT1a in WT and CD36-/- mice under HFD. (H) CPT1a protein 
level in HepG2 cells with PA treatment. (I) CPT1a mRNA level in WT and CD36-/- mice under 
HFD. Data were presented as the means ± SD, n=3 for (A-F, H), * represents p<0.05 vs. siNeg 
groups; # represents p<0.05 vs. siCD36 groups; n=6 for (G, I), * represents p<0.05, ** represents 




Figure 5. AMPK signalling is mechanistically involved in CD36-regulated autophagy. (A) 
Representative western blotting analysis of p-AMPK and t-AMPK levels in NCD and HFD 
mouse livers. (B) P-AMPK and t-AMPK levels in CD36-/- and WT mice under HFD. (C) 
P-AMPK, t-AMPK and LKB1 levels in HepG2 cells with PA treatment. (D) P-AMPK, t-AMPK, 
LC3II and p62 levels in siCD36 HepG2 cells with or without CC under the condition of PA 
treatment. (E) Lipid droplets in siCD36 HepG2 cells with or without CC under the condition of 
PA treatment. Data were presented as the means ± SD, n=6 for (A),* represents p<0.05 vs. NCD 
group; n=6 for (B), * represents p<0.05 vs. WT HFD group; n=3 for(C-E), * represents p<0.05 vs. 




Figure 6. Reducing CD36 expression increased autophagy through the phosphorylation of 
ULK1/Beclin1in the presence of PA. (A) Representative western blotting analysis of p-mTOR, 
mTOR, FOXO1, p-FOXO1, and ATG7 levels in siCD36 HepG2 cells. (B) mRNA level of 
FOXO1 in siCD36 HepG2 cells. (C-D) mRNA levels of several important ATGs, including ULK1, 
Beclin1, ATG5, ATG7, ATG12, ATG16L1 and ATG16L2, in siCD36 HepG2 and Huh7 cells. (E) 
mRNA levels of ULK1 and Beclin1 in CD36-/- and WT mice under HFD. (F) P-ULK1 and total 
ULK1 protein levels in siCD36 HepG2 cells. (G) P-ULK1 and total ULK1 protein levels in 
siCD36 HepG2 cells with or without CC. (H) P-Beclin1 and total Beclin1 protein levels in 
siCD36 Huh7 cells. Data were presented as the means ± SD, n=3 for (A-D, F-H), * represents 
p<0.05 vs. siNeg groups; # represents p<0.05 vs. siCD36 group; n=6 for (E), * represents p<0.05 
vs. WT HFD group. (I) The proposed model of CD36-mediated lipophagy. 
